APAC cholera vaccines market size, share, growth drivers, trends, opportunities & forecast 2025–2030

APAC Cholera Vaccines Market Overview

• The APAC Cholera Vaccines Market is valued at USD 30 million, based on a five-year historical analysis. This growth is primarily driven by increasing incidences of cholera outbreaks, heightened awareness regarding vaccination, and government initiatives to improve public health. The rising population in cholera-endemic regions and the need for preventive healthcare measures further contribute to the market's expansion. Recent trends highlight the expansion of manufacturing capacity in India and South Korea, as well as multilateral financing that secures multiyear procurement for large-scale preventive campaigns in India, Bangladesh, and Vietnam .
• Countries such as India, Bangladesh, and Myanmar dominate the APAC Cholera Vaccines Market due to their high population density and frequent cholera outbreaks. These nations have implemented extensive vaccination programs and public health campaigns, which have significantly increased the demand for cholera vaccines. Additionally, the presence of local manufacturers such as Bharat Biotech, Biological E., and EuBiologics enhances accessibility and affordability, further solidifying their market position .
• In 2023, the Indian government introduced a comprehensive cholera vaccination strategy aimed at reducing the incidence of the disease in high-risk areas. This initiative includes the allocation of USD 50 million for vaccine procurement and distribution, alongside public awareness campaigns to encourage vaccination among vulnerable populations. The strategy is aligned with the National Health Mission and is supported by the Ministry of Health and Family Welfare, Government of India, under the National Programme for Prevention and Control of Water-borne Diseases (2023), which mandates targeted immunization drives and reporting compliance for cholera-endemic districts .

APAC Cholera Vaccines Market Segmentation

By Product:The product segmentation of the APAC Cholera Vaccines Market includes various vaccines tailored to combat cholera effectively. The leading products in this segment are Dukoral, Shanchol, Euvichol & Euvichol-Plus, Vaxchora, and others. Among these, Shanchol has gained significant traction due to its affordability and effectiveness in cholera-endemic regions. The increasing focus on immunization programs by governments and NGOs has further propelled the demand for these vaccines. Shanchol and Euvichol-Plus are especially prominent in mass vaccination campaigns in India, Bangladesh, and Vietnam, while Dukoral is more often used for travelers .

By Vaccine Type:This segmentation includes inactivated (killed) oral vaccines, live attenuated oral vaccines, recombinant/subunit vaccines, and others. The inactivated oral vaccines are currently leading the market due to their established efficacy and safety profile. The preference for oral administration among populations in cholera-prone areas has also contributed to the dominance of this sub-segment, as it is easier to administer and requires no specialized medical training. Inactivated vaccines such as Shanchol and Euvichol are the mainstay of mass immunization programs, while live attenuated and recombinant vaccines are under development or used in specific scenarios .

APAC Cholera Vaccines Market Competitive Landscape

The APAC Cholera Vaccines Market is characterized by a dynamic mix of regional and international players. Leading participants such as Sanofi Pasteur, GlaxoSmithKline plc, Merck & Co., Inc., Valneva SE, Serum Institute of India Pvt. Ltd., Bharat Biotech International Limited, Biological E. Limited, EuBiologics Co., Ltd., Vaxart, Inc., Zydus Lifesciences Limited, Indian Immunologicals Limited, Chengdu Institute of Biological Products Co., Ltd., Institute of Infectious Diseases, Japan, National Institute of Cholera and Enteric Diseases (NICED), India, PATH contribute to innovation, geographic expansion, and service delivery in this space.

APAC Cholera Vaccines Market Industry Analysis

Growth Drivers

• Increasing Incidence of Cholera Outbreaks:The APAC region has witnessed over 1.4 million reported cholera cases in future, with countries like Bangladesh and India experiencing significant outbreaks. The World Health Organization (WHO) reported that cholera remains endemic in 12 countries in this region, necessitating urgent vaccination efforts. This alarming trend drives demand for cholera vaccines, as governments and health organizations prioritize immunization to curb the spread of the disease and protect vulnerable populations.
• Government Initiatives for Vaccination Programs:In future, the Indian government allocated approximately $55 million to enhance cholera vaccination programs, aiming to immunize over 12 million individuals in high-risk areas. Similar initiatives are observed in Bangladesh, where the government partnered with international organizations to distribute vaccines. These proactive measures reflect a commitment to public health and significantly contribute to the growth of the cholera vaccine market in the APAC region.
• Rising Awareness About Preventive Healthcare:The APAC region has seen a 35% increase in public awareness campaigns regarding cholera prevention in future. Health organizations are leveraging social media and community outreach to educate populations about the importance of vaccination. This heightened awareness is crucial, as it encourages individuals to seek vaccination, thereby driving demand for cholera vaccines and fostering a culture of preventive healthcare across the region.

Market Challenges

• Limited Access to Healthcare in Rural Areas:Approximately 62% of the APAC population resides in rural areas, where healthcare access remains a significant challenge. In countries like Myanmar and Laos, only 42% of rural residents have access to basic healthcare services. This disparity hampers vaccination efforts, as logistical challenges and lack of infrastructure prevent timely distribution of cholera vaccines, ultimately affecting public health outcomes in these regions.
• High Costs Associated with Vaccine Production:The production cost of cholera vaccines can exceed $2.75 per dose, which poses a barrier to widespread immunization, especially in low-income countries. With the APAC region's GDP per capita averaging around $3,800, many governments struggle to fund extensive vaccination programs. This financial constraint limits the ability to procure sufficient vaccines, hindering efforts to combat cholera outbreaks effectively.

APAC Cholera Vaccines Market Future Outlook

The APAC cholera vaccines market is poised for significant developments as governments and health organizations intensify their focus on vaccination strategies. With increasing incidences of cholera outbreaks, the demand for effective vaccines is expected to rise. Additionally, advancements in vaccine technology and formulation will likely enhance efficacy and accessibility. Collaborative efforts between public and private sectors will further strengthen vaccination initiatives, ensuring that underserved populations receive timely immunization against cholera, ultimately improving public health outcomes across the region.

Market Opportunities

• Expansion of Vaccination Programs in Underserved Regions:There is a significant opportunity to expand cholera vaccination programs in underserved regions, particularly in rural areas of Bangladesh and India. By targeting these populations, health organizations can reduce the incidence of cholera outbreaks and improve overall public health. Increased funding and partnerships with local NGOs can facilitate outreach and education efforts, ensuring that vulnerable communities receive necessary vaccinations.
• Partnerships with NGOs for Outreach:Collaborating with non-governmental organizations (NGOs) presents a valuable opportunity to enhance cholera vaccination efforts. NGOs often have established networks and local knowledge, enabling them to effectively reach at-risk populations. By leveraging these partnerships, governments can improve vaccine distribution and education, ultimately increasing vaccination rates and reducing the burden of cholera in the APAC region.